Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Accumulated Expenses: 2020-2025

Historic Other Accumulated Expenses for Tango Therapeutics (TNGX) over the last 4 years, with Sep 2025 value amounting to $1.7 million.

  • Tango Therapeutics' Other Accumulated Expenses fell 37.04% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 37.04%. This contributed to the annual value of $1.7 million for FY2024, which is 34.81% up from last year.
  • Latest data reveals that Tango Therapeutics reported Other Accumulated Expenses of $1.7 million as of Q3 2025, which was down 13.42% from $2.0 million recorded in Q2 2025.
  • Tango Therapeutics' Other Accumulated Expenses' 5-year high stood at $2.7 million during Q3 2024, with a 5-year trough of $666,000 in Q4 2021.
  • Its 3-year average for Other Accumulated Expenses is $1.8 million, with a median of $1.7 million in 2025.
  • In the last 5 years, Tango Therapeutics' Other Accumulated Expenses spiked by 90.83% in 2024 and then slumped by 37.04% in 2025.
  • Tango Therapeutics' Other Accumulated Expenses (Quarterly) stood at $666,000 in 2021, then soared by 90.24% to $1.3 million in 2022, then rose by 1.58% to $1.3 million in 2023, then spiked by 34.81% to $1.7 million in 2024, then tumbled by 37.04% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $2.0 million for Q2 2025, and $2.0 million during Q1 2025.